Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hanno Reinhard Hock, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Hanno Hock and Philip Amrein.
Connection Strength

0.676
  1. Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. Leuk Lymphoma. 2022 Jan 25; 1-8.
    View in: PubMed
    Score: 0.246
  2. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111.
    View in: PubMed
    Score: 0.213
  3. Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia. 2020 11; 34(11):3050-3054.
    View in: PubMed
    Score: 0.055
  4. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):e883-e889.
    View in: PubMed
    Score: 0.055
  5. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer. 2020 03 15; 126(6):1264-1273.
    View in: PubMed
    Score: 0.053
  6. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.053
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.